Antimicrobial stewardship programs in health care systems

被引:483
作者
MacDougall, C
Polk, RE
机构
[1] Univ Calif San Francisco, Sch Pharm, Dept Clin Pharm, San Francisco, CA 94143 USA
[2] Virginia Commonwealth Univ, Sch Pharm, Dept Pharm, Richmond, VA 23298 USA
关键词
D O I
10.1128/CMR.18.4.638-656.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Antimicrobial stewardship programs in hospitals seek to optimize antimicrobial prescribing in order to improve individual patient care as well as reduce hospital costs and slow the spread of antimicrobial resistance. With antimicrobial resistance on the rise worldwide and few new agents in development, antimicrobial stewardship programs are more important than ever in ensuring the continued efficacy of available antimicrobials. The design of antimicrobial management programs should be based on the best current understanding of the relationship between antimicrobial use and resistance. Such programs should be administered by multidisciplinary teams composed of infectious diseases physicians, clinical pharmacists, clinical microbiologists, and infection control practitioners and should be actively supported by hospital administrators. Strategies for changing antimicrobial prescribing behavior include education of prescribers regarding proper antimicrobial usage, creation of an antimicrobial formulary with restricted prescribing of targeted agents, and review of antimicrobial prescribing with feedback to prescribers. Clinical computer systems can aid in the implementation of each of these strategies, especially as expert systems able to provide patient-specific data and suggestions at the point of care. Antibiotic rotation strategies control the prescribing process by scheduled changes of antimicrobial classes used for empirical therapy. When instituting an antimicrobial stewardship program, a hospital should tailor its choice of strategies to its needs and available resources.
引用
收藏
页码:638 / +
页数:20
相关论文
共 164 条
[91]   Pharmacist participation on physician rounds and adverse drug events in the intensive care unit [J].
Leape, LL ;
Cullen, DJ ;
Clapp, MD ;
Burdick, E ;
Demonaco, HJ ;
Erickson, JI ;
Bates, DW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (03) :267-270
[92]  
Leibovici L, 1998, J INTERN MED, V244, P379
[93]   The population dynamics of antimicrobial chemotherapy [J].
Lipsitch, M ;
Levin, BR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :363-373
[94]   Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia [J].
Lodise, TP ;
McKinnon, PS ;
Swiderski, L ;
Rybak, MJ .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (11) :1418-1423
[95]   Antibiotic use in long-term-care facilities: Many unanswered questions [J].
Loeb, M .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2000, 21 (10) :680-683
[96]   Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use:: a time series analysis [J].
López-Lozano, JM ;
Monnet, DL ;
Yagüe, A ;
Burgos, A ;
Gonzalo, N ;
Campillos, P ;
Saez, M .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 14 (01) :21-31
[97]   Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia [J].
Luna, CM ;
Vujacich, P ;
Niederman, MS ;
Vay, C ;
Gherardi, C ;
Matera, J ;
Jolly, EC .
CHEST, 1997, 111 (03) :676-685
[98]   Adequacy of early empiric antibiotic treatment and survival in severe sepsis: Experience from the MONARCS trial [J].
MacArthur, RD ;
Miller, M ;
Albertson, T ;
Panacek, E ;
Johnson, D ;
Teoh, L ;
Barchuk, W .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (02) :284-288
[99]   Optimizing antibiotic use in hospitals: The role of population-based antibiotic surveillance in limiting antibiotic resistance - Insights from the Society of Infectious Diseases Pharmacists [J].
Madaras-Kelly, K .
PHARMACOTHERAPY, 2003, 23 (12) :1627-1633
[100]   Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia [J].
Mangili, A ;
Bica, I ;
Snydman, DR ;
Hamera, DH .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (07) :1058-1060